Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Feb. 14, 2023 | Jun. 30, 2022 | |
Cover [Abstract] | |||
Entity Registrant Name | Atrion Corporation | ||
Entity Central Index Key | 0000701288 | ||
Document Type | 10-K | ||
Amendment Flag | false | ||
Entity Voluntary Filers | No | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well Known Seasoned Issuer | No | ||
Entity Small Business | false | ||
Entity Shell Company | false | ||
Entity Emerging Growth Company | false | ||
Entity Current Reporting Status | Yes | ||
Document Period End Date | Dec. 31, 2022 | ||
Entity Filer Category | Large Accelerated Filer | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2022 | ||
Entity Common Stock Shares Outstanding | 1,761,478 | ||
Entity Public Float | $ 869,536,041 | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Entity File Number | 001-32982 | ||
Entity Incorporation State Country Code | DE | ||
Entity Tax Identification Number | 63-0821819 | ||
Entity Address Address Line 1 | One Allentown Parkway | ||
Entity Address City Or Town | Allen | ||
Entity Address State Or Province | TX | ||
Entity Address Postal Zip Code | 75002 | ||
City Area Code | 972 | ||
Local Phone Number | 390-9800 | ||
Security 12b Title | Common Stock, $0.10 Par Value | ||
Trading Symbol | ATRI | ||
Security Exchange Name | NASDAQ | ||
Entity Interactive Data Current | Yes | ||
Icfr Auditor Attestation Flag | true | ||
Auditor Name | GRANT THORNTON LLP | ||
Auditor Location | Dallas, Texas | ||
Auditor Firm Id | 248 |
CONSOLIDATED STATEMENTS OF INCO
CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
CONSOLIDATED STATEMENTS OF INCOME | |||
Revenues | $ 183,506 | $ 165,009 | $ 147,591 |
Cost of Goods Sold | 107,602 | 95,637 | 81,428 |
Gross Profit | 75,904 | 69,372 | 66,163 |
Operating Expenses: | |||
Selling | 9,782 | 8,061 | 7,520 |
General and administrative | 20,935 | 19,597 | 17,330 |
Research and development | 5,500 | 5,672 | 5,645 |
Total operating expenses | 36,217 | 33,330 | 30,495 |
Operating Income | 39,687 | 36,042 | 35,668 |
Interest and Dividend Income | 988 | 843 | 1,444 |
Other Investment Income (Loss) | (150) | 1,477 | 1,355 |
Other Income | 92 | 67 | |
Income before Provision for Income Taxes | 40,617 | 38,429 | 38,467 |
Provision for Income Taxes | (5,609) | (5,374) | (6,352) |
Net Income | $ 35,008 | $ 33,055 | $ 32,115 |
Net Income Per Basic Share | $ 19.59 | $ 18.22 | $ 17.49 |
Weighted Average Basic Shares Outstanding | 1,787 | 1,814 | 1,836 |
Net Income Per Diluted Share | $ 19.56 | $ 18.18 | $ 17.44 |
Weighted Average Diluted Shares Outstanding | 1,790 | 1,818 | 1,841 |
Dividends Per Common Share | $ 8.20 | $ 7.40 | $ 6.60 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Current Assets: | ||
Cash and cash equivalents | $ 4,731 | $ 32,264 |
Short-term investments | 21,152 | 29,059 |
Accounts receivable, net of allowance for doubtful accounts of $71 and $69 in 2022 and 2021, respectively | 23,951 | 21,023 |
Inventories | 65,793 | 50,778 |
Prepaid expenses and other current assets | 3,770 | 3,447 |
Total Current Assets | 119,397 | 136,571 |
Long-term investments | 8,669 | 19,423 |
Property, Plant and Equipment | 270,642 | 233,217 |
Less: accumulated depreciation | 146,888 | 135,245 |
Property, Plant And Equipment Net | 123,754 | 97,972 |
Other Assets and Deferred Charges: | ||
Patents and licenses, net of accumulated amortization of $12,655 and $12,538 in 2022 and 2021, respectively | 1,185 | 1,302 |
Goodwill | 9,730 | 9,730 |
Other | 1,977 | 2,266 |
Other Assets and Deferred Charges | 12,892 | 13,298 |
Total Assets | 264,712 | 267,264 |
Current Liabilities: | ||
Accounts payable | 12,074 | 7,146 |
Accrued liabilities | 5,950 | 5,930 |
Accrued income and other taxes | 74 | 270 |
Total Current Liabilities | 18,098 | 13,346 |
Line of credit | 0 | 0 |
Other Liabilities and Deferred Credits: | ||
Deferred income taxes | 3,888 | 7,082 |
Other | 3,185 | 2,540 |
Other Liabilities and Deferred Credits | 7,073 | 9,622 |
Total Liabilities | 25,171 | 22,968 |
Stockholders' Equity: | ||
Common stock, par value $0.10 per share, authorized 10,000 shares, issued 3,420 shares | 342 | 342 |
Additional paid-in capital | 66,347 | 61,174 |
Retained earnings | 377,682 | 357,324 |
Treasury shares, 1,659 shares in 2022 and 1,619 shares in 2021, at cost | (204,830) | (174,544) |
Total Stockholders' Equity | 239,541 | 244,296 |
Total Liabilities and Stockholders' Equity | $ 264,712 | $ 267,264 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
CONSOLIDATED BALANCE SHEETS | ||
Accounts receivable, net of allowance for doubtful accounts | $ 71 | $ 69 |
Patents and licenses, net of accumulated amortization | $ 12,655 | $ 12,538 |
Stockholders' equity | ||
Common stock, shares par value | $ 0.10 | $ 0.10 |
Common stock, shares authorized | 10,000,000 | 10,000,000 |
Common stock, shares issued | 3,420,000 | 3,420,000 |
Treasury stock, shares | 1,659,000 | 1,619,000 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Cash Flows From Operating Activities: | |||
Net income | $ 35,008 | $ 33,055 | $ 32,115 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 13,812 | 12,885 | 11,652 |
Deferred income taxes | (3,194) | (3,686) | 2,282 |
Stock-based compensation | 1,730 | 2,312 | 1,731 |
Net change in unrealized gains and losses on investments | 89 | (1,472) | (1,093) |
Net change in accrued interest, premiums, and discounts on investments | 119 | 632 | 112 |
Other | 0 | 22 | 21 |
Adjustments to reconcile net income to net cash provided by operating activities | 47,564 | 43,748 | 46,820 |
Changes in operating assets and liabilities: | |||
Accounts receivable | (2,928) | (4,579) | 2,438 |
Inventories | (15,015) | (480) | (8,205) |
Prepaid expenses and other current assets | (673) | 423 | (1,323) |
Other non-current assets | 640 | 11 | (275) |
Accounts payable and accrued liabilities | (1,247) | (656) | 2,095 |
Accrued income and other taxes | (196) | (165) | 17 |
Other non-current liabilities | 644 | 496 | (2,347) |
Cash flows from operating activities | 28,789 | 38,798 | 39,220 |
Cash Flows From Investing Activities: | |||
Property, plant and equipment additions | (33,736) | (15,828) | (21,886) |
Purchase of investments | (35,676) | (23,158) | (45,768) |
Proceeds from sale of investments | 245 | 793 | 899 |
Proceeds from maturities of investments | 53,884 | 40,189 | 35,923 |
Cash flows from investing activities | (15,283) | 1,996 | (30,832) |
Cash Flows From Financing Activities: | |||
Shares tendered for employees' withholding taxes on stock-based compensation | (633) | (585) | (55) |
Purchase of treasury stock | (25,786) | (16,988) | (18,831) |
Dividends paid | (14,620) | (13,407) | (12,100) |
Proceeds from draw on line of credit | 607 | 0 | 0 |
Repayment of draw on line of credit | (607) | 0 | 0 |
Cash flows from financing activities | (41,039) | (30,980) | (30,986) |
Net change in cash and cash equivalents | (27,533) | 9,814 | (22,598) |
Cash and cash equivalents, beginning of year | 32,264 | 22,450 | 45,048 |
Cash and cash equivalents, end of year | 4,731 | 32,264 | 22,450 |
Cash paid for: | |||
Income taxes, net of refunds | 9,876 | 7,744 | 5,565 |
Non-cash financing activities: | |||
Non-cash effect of stock option exercises | $ 4,007 | $ 6,012 | $ 0 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock | Treasury Stock | Additional Paid-In Capital | Retained Earnings |
Balance, shares at Dec. 31, 2019 | 1,855 | 1,565 | |||
Balance, amount at Dec. 31, 2019 | $ 237,870 | $ 342 | $ (132,260) | $ 52,043 | $ 317,745 |
Cumulative change in accounting principle | (36) | (36) | |||
Adjusted Balance at January 1, 2020, shares | 1,855 | 1,565 | |||
Adjusted Balance at January 1, 2020, amount | 237,834 | $ 342 | $ (132,260) | 52,043 | 317,709 |
Net income | 32,115 | 32,115 | |||
Stock-based compensation transactions | 1,503 | 19 | 1,484 | ||
Shares surrendered in stock transactions | (55) | $ (55) | |||
Purchase of treasury stock, shares | 29 | 29 | |||
Purchase of treasury stock, amount | (18,831) | $ (18,831) | |||
Dividends | 12,124 | 12,124 | |||
Balance, shares at Dec. 31, 2020 | 1,826 | 1,594 | |||
Balance, amount at Dec. 31, 2020 | 240,442 | $ 342 | $ (151,127) | 53,527 | 337,700 |
Net income | 33,055 | 33,055 | |||
Stock-based compensation transactions | 1,803 | $ (5,844) | 7,647 | ||
Purchase of treasury stock, shares | 28 | 28 | |||
Purchase of treasury stock, amount | (16,988) | $ (16,988) | |||
Dividends | 13,431 | 13,431 | |||
Stock-based compensation transactions, shares | 4 | (4) | |||
Shares surrendered in stock transactions, shares | (1) | 1 | |||
Shares surrendered in stock transactions, amount | (585) | $ (585) | |||
Balance, shares at Dec. 31, 2021 | 1,801 | 1,619 | |||
Balance, amount at Dec. 31, 2021 | 244,296 | $ 342 | $ (174,544) | 61,174 | 357,324 |
Net income | 35,008 | 35,008 | |||
Stock-based compensation transactions | 1,306 | $ (3,867) | 5,173 | ||
Purchase of treasury stock, shares | 43 | 43 | |||
Purchase of treasury stock, amount | (25,786) | $ (25,786) | |||
Dividends | 14,650 | 14,650 | |||
Stock-based compensation transactions, shares | 4 | (4) | |||
Shares surrendered in stock transactions, shares | (1) | 1 | |||
Shares surrendered in stock transactions, amount | (633) | $ (633) | |||
Balance, shares at Dec. 31, 2022 | 1,761 | 1,659 | |||
Balance, amount at Dec. 31, 2022 | $ 239,541 | $ 342 | $ (204,830) | $ 66,347 | $ 377,682 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2022 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | (1) Summary of Significant Accounting Policies Atrion Corporation and its subsidiaries (“we,” “our,” “us,” “Atrion,” or the “Company”) develop and manufacture products primarily for medical applications. We market our products throughout the United States and internationally. Our customers include physicians, hospitals, distributors, and other manufacturers. Atrion Corporation’s principal subsidiaries through which these operations are conducted are Atrion Medical Products, Inc., Halkey-Roberts Corporation, and Quest Medical, Inc. Principles of Consolidation The consolidated financial statements include the accounts of Atrion Corporation and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Certain prior-year balances have been reclassified in order to conform to the current year presentation. Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Cash and Cash Equivalents and Investments Cash and cash equivalents include cash on hand and cash deposits in the bank as well as money market funds and debt securities with maturities at the time of purchase of 90 days or less. Cash deposits in the bank include amounts in operating accounts, savings accounts, and money market accounts. Our investments consist of corporate and government bonds, commercial paper, mutual funds, and equity securities. We classify our investment securities in one of three categories: held-to-maturity, available-for-sale, or trading. Securities that we have the intent and ability to hold to maturity are reported at amortized cost and classified as held-to-maturity securities. We report our available-for-sale and trading securities at fair value with changes in fair value recognized in other investment income (loss) in the Consolidated Statements of Income. We consider as current assets those investments which will mature in the next 12 months including interest receivable on long-term bonds. The remaining investments are considered non-current assets which we intend to hold longer than 12 months. We periodically evaluate our investments for impairment. The components of the Company’s cash and cash equivalents and our short and long-term investments as of December 31, 2022 and 2021 are as follows (in thousands): December 31, 2022 December 31, 2021 Cash and cash equivalents: Cash deposits $ 603 $ 2,388 Money market funds 2,380 29,876 Commercial paper 1,748 - Total cash and cash equivalents $ 4,731 $ 32,264 Short-term investments: Commercial paper (held-to-maturity) $ 12,227 $ 2,248 Bonds (held-to-maturity) 8,597 26,831 Equity Securities (available for sale) 330 - Allowance for credit losses (2 ) (20 ) Total short-term investments $ 21,152 $ 29,059 Long-term investments: Equity securities (available for sale) $ 5,139 $ 5,468 Bonds (held-to-maturity) 3,180 13,405 Mutual funds (available for sale) 350 559 Allowance for credit losses - (9 ) Total long-term investments $ 8,669 $ 19,423 Total cash, cash equivalents and short and long-term investments $ 34,552 $ 80,746 Accounts Receivable Accounts receivable are recorded at the original sales price to the customer. We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments. The allowance for doubtful accounts is updated periodically to reflect our estimate of collectability. Accounts are written off when we determine the receivable will not be collected. Inventories Inventories are stated at the lower of cost (including materials, direct labor, and applicable overhead) or net realizable value. Cost is determined by using the first-in, first-out method. The following table details the major components of inventory (in thousands): December 31, 2022 2021 Raw materials $ 33,329 $ 23,733 Work in process 13,618 9,571 Finished goods 18,846 17,474 Total inventories $ 65,793 $ 50,778 Accounts Payable We reflect disbursements as trade accounts payable until such time as payments are presented to our bank for payment. Disbursements totaling approximately $887 thousand at December 31, 2022 and $1.989 million at December 31, 2021, had not been presented for payment to our bank. As of December 31, 2022, there were expenditures of $5.7 million related to property, plant, and equipment included in our accounts payable and accrued liabilities balance. Income Taxes We account for income taxes utilizing Accounting Standards Codification (ASC 740), Income Taxes ASC 740 also requires the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attributes of income tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the provision for income taxes unless it is more-likely-than-not of being sustained. Any uncertain tax positions are recorded within “Other non-current liabilities” in the accompanying consolidated balance sheets. We classify interest expense on underpayments of income taxes and accrued penalties related to unrecognized tax benefits in the income tax provision. We account for excess tax benefits (“windfalls”) and deficiencies (“shortfalls”) related to employee stock compensation as required by ASU 2016-09, Stock Compensation: Improvements to Employee Share-Based Payment Accounting We made quarterly payments in excess of federal and state income taxes due of approximately $1.0 million during the year ended December 31, 2022 and $345 thousand during the year ended December 31, 2021. These amounts were recorded in prepaid expenses and other current assets on our consolidated balance sheets. Property, Plant, and Equipment Property, plant, and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Additions and improvements are capitalized, including all material, labor, and engineering costs to design, install, or improve the asset. Expenditures for repairs and maintenance are charged to expense as incurred. The following table represents a summary of property, plant, and equipment at original cost (in thousands): December 31, Useful 2022 2021 Lives Land $ 5,511 $ 5,511 — Buildings 60,984 38,223 30-40 yrs. Machinery and equipment 204,147 189,483 3-15 yrs. Total property, plant and equipment $ 270,642 $ 233,217 Depreciation expense was $13.695 million in 2022, $12.767 million in 2021, and $11.533 million in 2020. Depreciation expense is recorded in either cost of goods sold or operating expenses based on the associated assets’ usage. Patents and Licenses Costs for patents and licenses acquired are determined at acquisition date. Patents and licenses are amortized over the useful lives of the individual patents and licenses, which are from seven to 20 years. Patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Goodwill Goodwill represents the excess of cost over the fair value of tangible and identifiable intangible net assets acquired. Annual impairment testing for goodwill is performed in the fourth quarter of each year using a qualitative assessment on goodwill impairment to determine whether it is more likely than not that the carrying value of our reporting units exceeds their fair value. If necessary, a two-step goodwill impairment analysis is performed. Goodwill is also reviewed whenever events or changes in circumstances indicate a change in value may have occurred. We have identified three reporting units where goodwill was recorded for purposes of testing goodwill impairment annually: (1) Atrion Medical Products, Inc., (2) Halkey-Roberts Corporation, and (3) Quest Medical, Inc. The total carrying amount of goodwill in each of the years ended December 31, 2022 and 2021 was $9.730 million. Our evaluation of goodwill during each year resulted in no impairment losses. Current Accrued Liabilities The items comprising current accrued liabilities are as follows (in thousands): December 31, 2022 2021 Accrued payroll and related expenses $ 4,718 $ 4,988 Accrued vacation 408 387 Other accrued liabilities 824 555 Total accrued liabilities $ 5,950 $ 5,930 Revenues We recognize revenue when obligations under the terms of a contract with our customer are satisfied. This occurs with the transfer of control of our products to customers when products are shipped. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Sales and other taxes we may collect concurrent with revenue-producing activities are excluded from revenue. We believe that our medical device business will benefit in the long term from an aging world population along with an increase in life expectancy. In the near term, however, demand for our products fluctuates based on our customers’ requirements which are driven in large part by their customers’ or patients’ needs for medical care which does not always follow broad economic trends. This affects the nature, amount, timing, and uncertainty of our revenue. Also, changes in the value of the United States dollar relative to foreign currencies could make our products more or less affordable and therefore affect our sales in international markets. A summary of revenues by geographic area, based on shipping destination, for 2022, 2021, and 2020 is as follows (in thousands): Year ended December 31, 2022 2021 2020 United States $ 109,740 $ 96,925 $ 85,682 European Union 30,311 28,657 27,786 All other regions 43,455 39,427 34,123 Total $ 183,506 $ 165,009 $ 147,591 A summary of revenues by product line for 2022, 2021 and 2020 is as follows (in thousands): Year ended December 31, 2022 2021 2020 Fluid Delivery $ 84,084 $ 77,753 $ 75,228 Cardiovascular 67,632 56,919 48,524 Ophthalmology 5,849 6,332 4,700 Other 25,941 24,005 19,139 Total $ 183,506 $ 165,009 $ 147,591 More than 98 percent of our total revenue in the periods presented herein is pursuant to shipments initiated by a purchase order. Under the guidance from Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers Our payment terms vary by the type and location of our customers and the products or services offered. The term between invoicing and when payment is due is 30 days in most cases. For certain products or services and customer types, we require payment before the products or services are delivered to the customer. We evaluate the collectability of specific accounts and determine when to grant credit to our customers using a combination of factors, including the age of the outstanding balances, evaluation of customers’ current and past financial condition, recent payment history, current economic environment, and discussions with our personnel and with the customers directly. We apply these same factors and more when evaluating certain aged receivables for collectability issues and to determine changes necessary to our allowance for doubtful accounts. If circumstances change, our estimates of the collectability of amounts could be changed by a material amount. We have elected to recognize the cost for shipping as an expense in cost of sales when control over the product has transferred to the customer. Shipping and handling fees charged to customers are reported as revenue. We do not make any material accruals for product returns and warranty obligations. Our manufactured products come with a standard warranty to be free from defect and, in the event of a defect, may be returned by the customer within a reasonable period of time. Historically, our returns have been unpredictable but very low due to our focus on quality control. A one-year warranty is provided with certain equipment sales but warranty claims and our accruals for these obligations have been minimal. We expense sales commissions when incurred because the amortization period would be one year or less. These costs are recorded within selling expense. Atrion has contracts in place with customers for equipment leases, equipment financing, and equipment and other services. These contracts represent less than four percent of our total revenue in all periods presented herein. A portion of these contracts contain multiple performance obligations including embedded leases. We treat agreements with an embedded lease component as a single performance obligation and recognize revenue under ASC 606 rather than under the lease accounting guidelines, since the predominant component of revenue is the non-lease component. Our fixed monthly equipment rentals to customers are accounted for as operating leases under ASU 2016-02, Leases (ASC 842). Fixed monthly rentals provide for a flat rental fee each month. A limited number of our contracts have variable consideration including tiered pricing and rebates which we monitor closely for potential constraints on revenue. For these contracts, we estimate our position quarterly using the most-likely-outcome method, including customer-provided forecasts and historical buying patterns, and we accrue for any asset or liability these arrangements may create. The effect of accruals for variable consideration on our consolidated financial statements is immaterial. We do not disclose the value of unsatisfied performance obligations for contracts for which we recognize revenue at the amount which we have the right to invoice. We believe that the complexity added to our disclosures by the inclusion of a large amount of insignificant detail in attempting to disclose information under ASC 606 about immaterial contracts would potentially obscure more useful and important information. Leases to Customers The lease assets from our sales-type leases are recorded in our accounts receivable in the accompanying consolidated balance sheets, and the balance totaled $356 thousand as of December 31, 2022 and $470 thousand as of December 31, 2021. Our equipment treated as leases to customers is included in Property, Plant, and Equipment on our consolidated balance sheets. Due to the immaterial amount of revenue and assets from our lessor activity, all other lessor disclosures have been omitted. Leased Property and Equipment As a lessee, we had eight leases in total for equipment and facilities used internally during 2022, which we account for as operating leases. At December 31, 2022, our right-of-use asset balance was $683 thousand and our lease liability at December 31, 2022 for these leases was $672 thousand. The monthly expense of $43 thousand for these operating leases, which are our only lessee arrangements, is immaterial and therefore all other lessee disclosures have been omitted. Research and Development Costs Research and Development, or R&D, costs relating to the development of new products and improvements of existing products are expensed as incurred. Stock-Based Compensation We have a stock-based compensation plan covering certain of our officers, directors, key employees, and non-physician consultants. As explained in detail in Note 8, we account for stock-based compensation utilizing the fair value recognition provisions of ASC 718, Compensation-Stock Compensation, Liability-classified Awards The Company classifies certain awards that can or will be settled in cash as liability awards. The fair value of a liability-classified award is determined on a quarterly basis beginning at the grant date until final vesting. Changes in the fair value of liability-classified awards are recorded to general and administrative expense over the vesting period of the award. New Accounting Pronouncements From time to time new accounting pronouncements applicable to us are issued by the FASB, or other standards setting bodies, which we adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption. Fair Value Measurements Accounting standards use a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists therefore requiring an entity to develop its own assumptions. As of December 31, 2022 and 2021, we held investments in commercial paper, bonds, money market funds, mutual funds, and equity securities that are required to be measured for disclosure purposes at fair value on a recurring basis. The fair values of these investments and their tier levels are shown in Note 2. The carrying values of our other financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and accrued income and other taxes approximated fair value due to their liquid and short-term nature. Concentration of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, and accounts receivable. Our cash deposits are held in accounts with financial institutions that we believe are creditworthy. Certain of these amounts at times may exceed federally-insured limits. We have investments in money market funds, bonds, equity securities, and commercial paper. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, changes in credit quality of the issuer, and otherwise. These securities have a higher degree of, and a greater exposure to, credit or default risk and may be less liquid in times of economic weakness or market disruptions as compared with cash deposits. For accounts receivable, we perform ongoing credit evaluations of our customers’ financial condition and generally do not require collateral. We maintain reserves for possible credit losses. We had allowances for doubtful accounts of approximately $71 thousand at December 31, 2022 and $69 thousand, at December 31, 2021. The carrying amount of the receivables approximates their fair value. |
Investments
Investments | 12 Months Ended |
Dec. 31, 2022 | |
Investments | |
Investments | (2) Investments As of December 31, 2022 and 2021, we held investments in commercial paper, bonds, money market accounts, mutual funds, and equity securities. The commercial paper and bonds are considered held-to-maturity and are recorded at amortized cost in the accompanying consolidated balance sheets. The money market accounts, equity securities, and mutual funds are recorded at fair value in the accompanying consolidated balance sheets. These investments are considered Level 1 or Level 2 as detailed in the table below. The amortized cost and fair value of our investments, and the related gross unrealized gains and losses, were as follows as of the dates shown below (in thousands): Gross Unrealized Level Cost Gains Losses Fair Value As of December 31, 2022: Money market funds 1 $ 2,380 $ - $ - $ 2,380 Commercial paper 2 $ 13,975 $ 1 $ (9 ) $ 13,967 Bonds 2 $ 11,777 $ - $ (353 ) $ 11,424 Mutual funds 1 $ 466 $ - $ (116 ) $ 350 Equity investments 2 $ 6,054 $ - $ (585 ) $ 5,469 As of December 31, 2021: Money market funds 1 $ 29,876 $ - $ - $ 29,876 Commercial paper 2 $ 2,248 $ - $ - $ 2,248 Bonds 2 $ 40,236 $ 97 $ (37 ) $ 40,296 Mutual funds 1 $ 558 $ 1 $ - $ 559 Equity investments 2 $ 5,675 $ - $ (207 ) $ 5,468 The above equity investments represent an investment in two companies at December 31, 2022 and are classified as available for sale. The carrying value of our investments is reviewed quarterly for changes in circumstances or the occurrence of events that suggest an investment may not be recoverable. As of December 31, 2022, we had seven bond investments in a loss position for more than 12 months. At December 31, 2022, the length of time until maturity of the bonds we currently own ranged from one to 36 months and the length of time until maturity of the commercial paper ranged from one to four months. We use a lifetime “expected credit loss” measurement objective for the recognition of credit losses for held-to-maturity securities at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. Our credit loss calculations for held-to-maturity securities are based upon historical default and recovery rates of bonds rated with the same rating as our portfolio. We also apply an adjustment factor to these credit loss calculations based upon our assessment of the expected impact from current economic conditions on our investments. We monitor the credit quality of debt securities classified as held-to-maturity through the use of their respective credit ratings and update them on a quarterly basis with our latest assessment completed on December 31, 2022. Our allowance for credit losses was $2 thousand as of December 31, 2022 and $29 thousand as of December 31, 2021. The decrease in allowance was primarily due to the decrease in the balance of the underlying assets. The following table summarizes the amortized cost of our held-to-maturity bonds at December 31, 2022, aggregated by credit quality indicator (in thousands): Held-to-Maturity Bonds Credit Quality Indicators Fed Govt. Bonds/Notes Municipal Bonds Corporate Bonds Total AA/A $ 180 $ - $ 3,044 $ 3,224 BBB - - 8,553 8,553 TOTAL $ 180 $ - $ 11,597 $ 11,777 |
Patents and Licenses
Patents and Licenses | 12 Months Ended |
Dec. 31, 2022 | |
Patents and Licenses | |
Patents and Licenses | (3) Patents and Licenses Patents and license fees paid for the use of other entities’ patents are amortized over the useful life of the patent or license. The following tables provide information regarding patents and licenses (dollars in thousands): December 31, 2022 December 31, 2021 Weighted Average Original Life (years) Gross Carrying Amount Accumulated Amortization Weighted Average Original Life (years) Gross Carrying Amount Accumulated Amortization 15.67 $ 13,840 $ 12,655 15.67 $ 13,840 $ 12,538 Aggregate amortization expense for patents and licenses was $117 thousand for 2022 and $119 thousand for 2021. Estimated future amortization expense for each of the years set forth below ending December 31 is as follows (in thousands): 2023 $ 113 2024 $ 113 2025 $ 112 2026 $ 112 2027 $ 108 |
Line of Credit
Line of Credit | 12 Months Ended |
Dec. 31, 2022 | |
Line of Credit | |
Line of Credit | (4) Line of Credit As of December 31, 2022 and 2021, we had a $75.0 million revolving credit facility with a money-center bank pursuant to which the lender is obligated to make advances until February 28, 2024. On February 12, 2021, this credit facility was amended to, among other things, extend the date for advances to February 28, 2024. The credit facility is secured by substantially all our inventories, equipment, and accounts receivable. The interest rate on borrowings under this credit facility is indexed to the 30-day, 60-day, or 90-day LIBOR, as selected by us, and was immaterial in 2022. We had no outstanding borrowings under the credit facility at December 31, 2022 or December 31, 2021. Our ability to borrow funds under the credit facility is contingent upon meeting certain covenants in the loan agreement, the most restrictive of which is the ratio of total debt to earnings before interest, income tax, depreciation, and amortization. At December 31, 2022, we were in compliance with all of the covenants. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2022 | |
Income Taxes | |
Income taxes | (5) Income Taxes The items comprising Provision for Income Taxes are as follows (in thousands): Year ended December 31, 2022 2021 2020 Current — Federal $ 8,030 $ 7,445 $ 3,166 — State 773 1,615 904 8,803 9,060 4,070 Deferred — Federal (3,021 ) (3,349 ) 2,111 — State (173 ) (337 ) 171 (3,194 ) (3,686 ) 2,282 Provision for Income Taxes $ 5,609 $ 5,374 $ 6,352 Temporary differences and carryforwards which have given rise to deferred tax assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): 2022 2021 Deferred tax assets Benefit plans $ 1,421 $ 1,853 Inventories 730 336 Capitalized R&D 2,275 -- Total deferred tax assets 4,426 2,189 Valuation allowance -- (36 ) Net deferred tax assets 4,426 2,153 Deferred tax liabilities Property, plant, and equipment 6,334 7,289 Patents and goodwill 1,745 1,773 Other 235 173 Total deferred tax liabilities 8,314 9,235 Net deferred tax liabilities $ 3,888 $ 7,082 Total income tax expense differs from the amount that would be provided by applying the statutory federal income tax rate to pretax earnings as illustrated below (in thousands): Year ended December 31, 2022 2021 2020 Income tax expense at the statutory federal income tax rate $ 8,530 $ 8,070 $ 8,078 Increase (decrease) resulting from: State income taxes 438 1,027 839 R&D tax credits (1,332 ) (1,703 ) (1,589 ) Foreign-derived intangible income deduction (2,133 ) (2,091 ) (1,051 ) Excess tax benefit from stock compensation (97 ) (185 ) (81 ) Uncertain tax positions -- -- (450 ) Other, net 203 256 606 Provision for Income Taxes $ 5,609 $ 5,374 $ 6,352 A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands): Gross unrecognized tax benefits at January 1, 2020 $ 450 Increase in tax positions for prior years 8 Increase in tax positions for current years -- Lapse in statutes of limitation (458 ) Gross unrecognized tax benefits at December 31, 2020 $ -- Increase in tax positions for prior years -- Increase in tax positions for current year -- Lapse in statutes of limitation -- Gross unrecognized tax benefits at December 31, 2021 $ -- Increase in tax positions for prior years -- Increase in tax positions for current year -- Lapse in statutes of limitation -- Gross unrecognized tax benefits at December 31, 2022 $ -- We are subject to United States federal income tax as well as to income tax of multiple state jurisdictions. We have concluded all United States federal income tax matters, as well as all material state and local income tax matters, for years through 2017. The Internal Revenue Service is currently auditing our 2018 federal tax return. On August 16, 2022, the “Inflation Reduction Act” (H.R. 5376) was signed into law in the United States. We do not currently expect the Inflation Reduction Act to have a material impact on our financial results, including on our annual estimated effective tax rate or on our liquidity. We recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. Tax expense included a net interest benefit of zero for the years ended December 31, 2022 and December 31, 2021 and $35 thousand for the year ended December 31, 2020. |
Stockholders Equity
Stockholders Equity | 12 Months Ended |
Dec. 31, 2022 | |
Stockholders' Equity: | |
Stockholders's Equity | (6) Stockholders’ Equity Our Board of Directors has at various times authorized repurchases of our stock in open-market or privately-negotiated transactions at such times and at such prices as management or the Board of Directors may from time to time determine. On May 21, 2015, our Board of Directors adopted a stock repurchase program authorizing the repurchase of up to 250 thousand shares of our common stock in open-market or privately-negotiated transactions. This program has no expiration date but may be terminated by the Board of Directors at any time. As of December 31, 2022, there remained 131,622 shares available for repurchase under this program. As of December 31, 2021, there remained 174,190 shares available for repurchase under this program. We repurchased a total of 42,568 shares of our common stock during 2022 and 27,828 shares in 2021 in open-market transactions. We have increased our quarterly cash dividend rate in September of each of the past three years. The quarterly dividend rate was increased to $1.75 per share in September 2020, to $1.95 per share in September 2021, and to $2.15 per share in September 2022. Holders of our stock units earned non-cash dividend equivalents of $30 thousand in 2022 and $24 thousand in each of the years 2021 and 2020. |
Income Per Share
Income Per Share | 12 Months Ended |
Dec. 31, 2022 | |
Income Per Share | |
Income Per Share | (7) Income Per Share The following is the computation of basic and diluted net income per share: Year ended December 31, 2022 2021 2020 (In thousands, except per share amounts) Net Income $ 35,008 $ 33,055 $ 32,115 Weighted average basic shares outstanding 1,787 1,814 1,836 Add: Effect of dilutive securities 3 4 5 Weighted average diluted shares outstanding 1,790 1,818 1,841 Net Income per share Basic $ 19.59 $ 18.22 $ 17.49 Diluted $ 19.56 $ 18.18 $ 17.44 Nonvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are considered participating securities and, therefore, are included in the computation of basic income per share pursuant to the two-class method. Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method. Potentially dilutive securities have been excluded when their inclusion would be anti-dilutive. For the year ended December 31, 2022, there were no shares with an anti-dilutive effect. We excluded two shares of our common stock for the year ended December 31, 2021 and six shares of common stock for the year ended December 31, 2020. |
Stockbased Compensation
Stockbased Compensation | 12 Months Ended |
Dec. 31, 2022 | |
Stockbased Compensation | |
Stock-based Compensation | (8) Stock-based Compensation At December 31, 2022, we had two stock-based compensation plans described below. Our 2021 Equity Incentive Plan, or 2021 Plan, and our Amended and Restated 2006 Equity Incentive Plan, or 2006 Plan, provide for awards to key employees, non-employee directors, and consultants of incentive and nonqualified stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance shares, and other stock-based awards. Under the 2021 Plan, 100,000 shares, in the aggregate, of common stock are reserved for awards, and under the 2006 Plan, 200,000 shares, in the aggregate, of common stock were reserved for awards. As of December 31, 2021, no future stock-based awards are permitted under the 2006 plan. The purchase price of shares issued on the exercise of options under both plans is required to be at least equal to the fair market value of such shares on the date of grant. The options granted become exercisable and expire as determined by the Compensation Committee. A summary of stock option transactions for the year ended December 31, 2022, is presented below: Options Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Outstanding at December 31, 2021 8,000 $ 501.03 0.3 years Granted -- -- Exercised 8,000 -- Outstanding at December 31, 2022 -- -- -- There were no outstanding options remaining at December 31, 2022. None of our grants includes performance-based or market-based vesting conditions. There were no restricted stock grants during 2022 or 2021. During 2017, we granted two awards of restricted stock under the 2006 Plan. Under the terms of our restricted stock awards, the restrictions usually lapse over a five-year period. Both of the 2017 awards include restrictions on transfer for a two-year period following vesting. Under both plans, during the vesting period holders of restricted stock have voting rights and earn dividends, but the shares may not be sold, assigned, transferred, pledged, or otherwise encumbered. Nonvested shares are generally forfeited on termination of employment unless otherwise provided in the participant’s employment agreement or the termination is in connection with a change in control. We calculated the weighted average fair value per share of the restricted stock awarded in 2017 using the market value of our common stock on the date of the grant with a discount for post-vesting restrictions of 11.2%. We estimated this discount using the Chaffe protective put method. A summary of changes in nonvested restricted stock for the year ended December 31, 2022, is presented below: Nonvested Shares Shares Weighted Average Award Date Fair Value Per Share Restricted stock at December 31, 2021 1,180 $ 445.47 Granted -- -- Vested (1,180 ) $ 445.47 Restricted stock at December 31, 2022 -- -- There were no remaining nonvested shares of restricted stock outstanding at December 31, 2022. The total fair value of restricted stock was $796 thousand for stock vested in 2022, $754 thousand for stock vested during 2021, and $762 thousand for stock vested in 2020. During 2022, restricted stock units were granted to certain employees. All of our restricted stock units granted under both plans are convertible to shares of stock on a one-for-one basis when the restrictions lapse, which is generally after a five-year period. Nonvested restricted stock units are generally forfeited upon termination of employment unless the termination is in connection with a change in control. Under both plans, during the vesting period, holders of restricted stock units earn dividends in the form of additional units. A summary of changes in stock units for the year ended December 31, 2022, is presented below: Nonvested Stock Units Restricted Stock Units Weighted Average Award Date Fair Value Per Unit Director’s Stock Units Weighted Average Award Date Fair Value Per Unit Nonvested at December 31, 2021 4,171 $ 666.14 -- Granted & Added 644 $ 618.99 7 $ 616.83 Forfeited (374 ) $ 649.30 -- Vested (1,711 ) $ 613.21 (7 ) $ 616.83 Nonvested at December 31, 2022 2,730 $ 690.50 -- All nonvested restricted stock units at December 31, 2022 are expected to vest. The total intrinsic value of these outstanding stock units which were not convertible at December 31, 2022, including 515 stock units held for the accounts of non-employee directors, was $1.8 million. The total fair value of directors’ stock units was $4 thousand for units that vested during each of the years ended December 31, 2022 and 2021 and $11 thousand for units that vested during 2020. During 2020, we granted 3,865 restricted stock units outside of the plans to three employees that will be settled in cash and are treated as liability-classified awards. The grant-date fair value per unit for these awards was $646.90. No grants of this type were made outside the plans prior to 2020. These units vest 20 percent each year over a five-year period beginning in 2021. Changes in the fair value of these awards are recorded to G&A expense over the vesting period of the award. The liability recorded for these units is adjusted to the current market value at the end of each reporting period. We paid cash of $524 thousand to settle the 20 percent vesting in 2022 and $485 thousand to settle the 20 percent vesting in 2021. At December 31, 2022, our recorded liability for the remaining units was $227 thousand. The intrinsic value of these units at December 31, 2022 was $1.304 million including accrued amounts for dividend equivalents. The total value of stock awards to nonemployee directors awarded under the plans was $492 thousand in 2022 and $432 thousand in 2021. No stock awards were granted in 2020. These awards vested immediately at the time of the grants. Compensation related to stock option awards, restricted stock, and restricted stock units that are treated as equity-classified awards is based on the fair market value of the stock on the date of the award. These fair values are then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. We recorded stock-based compensation expense as a G&A expense in the amount of $1.730 million for the year ended December 31, 2022, $2.312 million for the year ended December 31, 2021, and $1.731 million for the year ended December 31 2020, for all of the above-mentioned stock-based compensation arrangements. The total tax benefit recognized in the income statement from stock-based compensation arrangements was $461 thousand for the year ended December 31, 2022, $1.203 million for the year ended December 31, 2021, and $444 thousand for the year ended December 31, 2020. These amounts include excess tax benefits in each year. Unrecognized compensation cost information for our various stock-based compensation awards is shown below as of December 31, 2022 (in thousands): Unrecognized Compensation Cost Weighted Average Remaining Years in Amortization Period Stock options $ -- -- Restricted stock -- -- Restricted stock units 1,079 3.4 Restricted stock units (to be settled in cash) 1,304 2.5 Total $ 2,383 We have a policy of utilizing treasury shares to satisfy stock option exercises, stock unit conversions, and restricted stock awards that are equity-classified awards. |
Industry Segment and Geographic
Industry Segment and Geographic Information | 12 Months Ended |
Dec. 31, 2022 | |
Industry Segment and Geographic Information | (9) Industry Segment and Geographic Information We operate in one reportable industry segment: developing and manufacturing products primarily for medical applications. We have no foreign operating subsidiaries. We have other product lines which include pressure relief valves and inflation systems, which are sold primarily to the aviation and marine industries. Due to the similarities in product technologies and manufacturing processes, these products are managed as part of our medical products segment. Our revenues from sales to customers outside the United States totaled approximately 40 percent of our net revenues in 2022, 41 percent in 2021, and 42 percent in 2020. We have no assets located outside the United States. |
Employee Retirement and Benefit
Employee Retirement and Benefit Plans | 12 Months Ended |
Dec. 31, 2022 | |
Employee Retirement and Benefit Plans | |
Employee Retirement and Benefit Plans | (10) Employee Retirement and Benefit Plans We sponsor a defined contribution 401(k) plan for all employees. Each participant may contribute certain amounts of eligible compensation. We make a matching contribution to the plan. Our contributions under this plan were $1.061 million in 2022, $980 thousand in 2021, and $917 thousand in 2020. The Company has a Nonqualified Deferred Compensation Plan for certain key management or highly-compensated employees. The plan allows for the deferral of salary and bonus compensation until retirement or other specified payment events occur. Employees’ deferred compensation amounts are deemed to be invested in certain investment funds, indexes, or vehicles selected by our Compensation Committee and designated by each participant and their deferral balances are adjusted for earnings based upon the performance of these deemed investments. Our deferred compensation obligation under the plan was $2.355 million at December 31, 2022 and $2.031 million at December 31 2021. These amounts are reflected in “Other Liabilities and Deferred Credits” in the accompanying consolidated balance sheets. |
Commitment and Contingencies
Commitment and Contingencies | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies | |
Commitment and Contingencies | (11) Commitments and Contingencies From time to time and in the ordinary course of business, we may be subject to various claims, charges, and litigation. In some cases, the claimants may seek damages, as well as other relief, which, if granted, could require significant expenditures. We accrue the estimated costs of settlement or damages when a loss is deemed probable and such costs are estimable, and accrue for legal costs associated with a loss contingency when a loss is probable and such amounts are estimable. Otherwise, these costs are expensed as incurred. If the estimate of a probable loss or defense costs is a range and no amount within the range is more likely, we accrue the minimum amount of the range. As of December 31, 2022, we had no ongoing litigation or arbitration for such matters. We had a dispute which was favorably settled in the third quarter of 2007. This settlement was amended in December 2008. The amended settlement agreement provides that we may receive annual payments from 2009 through 2024. We have not recorded $1.0 million in potential future payments under this settlement as of December 31, 2022 due to the uncertainty of payment. We have arrangements with three of our executive officers pursuant to which the termination of their employment under certain circumstances would result in lump sum payments to them. Termination under such circumstances at December 31, 2022, could have resulted in payments aggregating $5.4 million. At December 31, 2022, the Company had lease obligations totaling $672 thousand with certain lessors for equipment and facilities. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Summary of Significant Accounting Policies | |
Principles of Consolidation | The consolidated financial statements include the accounts of Atrion Corporation and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Certain prior-year balances have been reclassified in order to conform to the current year presentation. |
Estimates | The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. |
Cash and Cash Equivalents and Investments | Cash and cash equivalents include cash on hand and cash deposits in the bank as well as money market funds and debt securities with maturities at the time of purchase of 90 days or less. Cash deposits in the bank include amounts in operating accounts, savings accounts, and money market accounts. Our investments consist of corporate and government bonds, commercial paper, mutual funds, and equity securities. We classify our investment securities in one of three categories: held-to-maturity, available-for-sale, or trading. Securities that we have the intent and ability to hold to maturity are reported at amortized cost and classified as held-to-maturity securities. We report our available-for-sale and trading securities at fair value with changes in fair value recognized in other investment income (loss) in the Consolidated Statements of Income. We consider as current assets those investments which will mature in the next 12 months including interest receivable on long-term bonds. The remaining investments are considered non-current assets which we intend to hold longer than 12 months. We periodically evaluate our investments for impairment. The components of the Company’s cash and cash equivalents and our short and long-term investments as of December 31, 2022 and 2021 are as follows (in thousands): December 31, 2022 December 31, 2021 Cash and cash equivalents: Cash deposits $ 603 $ 2,388 Money market funds 2,380 29,876 Commercial paper 1,748 - Total cash and cash equivalents $ 4,731 $ 32,264 Short-term investments: Commercial paper (held-to-maturity) $ 12,227 $ 2,248 Bonds (held-to-maturity) 8,597 26,831 Equity Securities (available for sale) 330 - Allowance for credit losses (2 ) (20 ) Total short-term investments $ 21,152 $ 29,059 Long-term investments: Equity securities (available for sale) $ 5,139 $ 5,468 Bonds (held-to-maturity) 3,180 13,405 Mutual funds (available for sale) 350 559 Allowance for credit losses - (9 ) Total long-term investments $ 8,669 $ 19,423 Total cash, cash equivalents and short and long-term investments $ 34,552 $ 80,746 |
Account Receivables | Accounts receivable are recorded at the original sales price to the customer. We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments. The allowance for doubtful accounts is updated periodically to reflect our estimate of collectability. Accounts are written off when we determine the receivable will not be collected. |
Inventories | Inventories are stated at the lower of cost (including materials, direct labor, and applicable overhead) or net realizable value. Cost is determined by using the first-in, first-out method. The following table details the major components of inventory (in thousands): December 31, 2022 2021 Raw materials $ 33,329 $ 23,733 Work in process 13,618 9,571 Finished goods 18,846 17,474 Total inventories $ 65,793 $ 50,778 |
Accounts Payable | We reflect disbursements as trade accounts payable until such time as payments are presented to our bank for payment. Disbursements totaling approximately $887 thousand at December 31, 2022 and $1.989 million at December 31, 2021, had not been presented for payment to our bank. As of December 31, 2022, there were expenditures of $5.7 million related to property, plant, and equipment included in our accounts payable and accrued liabilities balance. |
Income Taxes | We account for income taxes utilizing Accounting Standards Codification (ASC 740), Income Taxes ASC 740 also requires the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attributes of income tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the provision for income taxes unless it is more-likely-than-not of being sustained. Any uncertain tax positions are recorded within “Other non-current liabilities” in the accompanying consolidated balance sheets. We classify interest expense on underpayments of income taxes and accrued penalties related to unrecognized tax benefits in the income tax provision. We account for excess tax benefits (“windfalls”) and deficiencies (“shortfalls”) related to employee stock compensation as required by ASU 2016-09, Stock Compensation: Improvements to Employee Share-Based Payment Accounting We made quarterly payments in excess of federal and state income taxes due of approximately $1.0 million during the year ended December 31, 2022 and $345 thousand during the year ended December 31, 2021. These amounts were recorded in prepaid expenses and other current assets on our consolidated balance sheets. |
Property, Plant and Equipment | Property, plant, and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Additions and improvements are capitalized, including all material, labor, and engineering costs to design, install, or improve the asset. Expenditures for repairs and maintenance are charged to expense as incurred. The following table represents a summary of property, plant, and equipment at original cost (in thousands): December 31, Useful 2022 2021 Lives Land $ 5,511 $ 5,511 — Buildings 60,984 38,223 30-40 yrs. Machinery and equipment 204,147 189,483 3-15 yrs. Total property, plant and equipment $ 270,642 $ 233,217 Depreciation expense was $13.695 million in 2022, $12.767 million in 2021, and $11.533 million in 2020. Depreciation expense is recorded in either cost of goods sold or operating expenses based on the associated assets’ usage. |
Patents and Licenses | Costs for patents and licenses acquired are determined at acquisition date. Patents and licenses are amortized over the useful lives of the individual patents and licenses, which are from seven to 20 years. Patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. |
Goodwill | Goodwill represents the excess of cost over the fair value of tangible and identifiable intangible net assets acquired. Annual impairment testing for goodwill is performed in the fourth quarter of each year using a qualitative assessment on goodwill impairment to determine whether it is more likely than not that the carrying value of our reporting units exceeds their fair value. If necessary, a two-step goodwill impairment analysis is performed. Goodwill is also reviewed whenever events or changes in circumstances indicate a change in value may have occurred. We have identified three reporting units where goodwill was recorded for purposes of testing goodwill impairment annually: (1) Atrion Medical Products, Inc., (2) Halkey-Roberts Corporation, and (3) Quest Medical, Inc. The total carrying amount of goodwill in each of the years ended December 31, 2022 and 2021 was $9.730 million. Our evaluation of goodwill during each year resulted in no impairment losses. |
Current Accrued Liabilities | The items comprising current accrued liabilities are as follows (in thousands): December 31, 2022 2021 Accrued payroll and related expenses $ 4,718 $ 4,988 Accrued vacation 408 387 Other accrued liabilities 824 555 Total accrued liabilities $ 5,950 $ 5,930 |
Revenues | We recognize revenue when obligations under the terms of a contract with our customer are satisfied. This occurs with the transfer of control of our products to customers when products are shipped. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Sales and other taxes we may collect concurrent with revenue-producing activities are excluded from revenue. We believe that our medical device business will benefit in the long term from an aging world population along with an increase in life expectancy. In the near term, however, demand for our products fluctuates based on our customers’ requirements which are driven in large part by their customers’ or patients’ needs for medical care which does not always follow broad economic trends. This affects the nature, amount, timing, and uncertainty of our revenue. Also, changes in the value of the United States dollar relative to foreign currencies could make our products more or less affordable and therefore affect our sales in international markets. A summary of revenues by geographic area, based on shipping destination, for 2022, 2021, and 2020 is as follows (in thousands): Year ended December 31, 2022 2021 2020 United States $ 109,740 $ 96,925 $ 85,682 European Union 30,311 28,657 27,786 All other regions 43,455 39,427 34,123 Total $ 183,506 $ 165,009 $ 147,591 A summary of revenues by product line for 2022, 2021 and 2020 is as follows (in thousands): Year ended December 31, 2022 2021 2020 Fluid Delivery $ 84,084 $ 77,753 $ 75,228 Cardiovascular 67,632 56,919 48,524 Ophthalmology 5,849 6,332 4,700 Other 25,941 24,005 19,139 Total $ 183,506 $ 165,009 $ 147,591 More than 98 percent of our total revenue in the periods presented herein is pursuant to shipments initiated by a purchase order. Under the guidance from Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers Our payment terms vary by the type and location of our customers and the products or services offered. The term between invoicing and when payment is due is 30 days in most cases. For certain products or services and customer types, we require payment before the products or services are delivered to the customer. We evaluate the collectability of specific accounts and determine when to grant credit to our customers using a combination of factors, including the age of the outstanding balances, evaluation of customers’ current and past financial condition, recent payment history, current economic environment, and discussions with our personnel and with the customers directly. We apply these same factors and more when evaluating certain aged receivables for collectability issues and to determine changes necessary to our allowance for doubtful accounts. If circumstances change, our estimates of the collectability of amounts could be changed by a material amount. We have elected to recognize the cost for shipping as an expense in cost of sales when control over the product has transferred to the customer. Shipping and handling fees charged to customers are reported as revenue. We do not make any material accruals for product returns and warranty obligations. Our manufactured products come with a standard warranty to be free from defect and, in the event of a defect, may be returned by the customer within a reasonable period of time. Historically, our returns have been unpredictable but very low due to our focus on quality control. A one-year warranty is provided with certain equipment sales but warranty claims and our accruals for these obligations have been minimal. We expense sales commissions when incurred because the amortization period would be one year or less. These costs are recorded within selling expense. Atrion has contracts in place with customers for equipment leases, equipment financing, and equipment and other services. These contracts represent less than four percent of our total revenue in all periods presented herein. A portion of these contracts contain multiple performance obligations including embedded leases. We treat agreements with an embedded lease component as a single performance obligation and recognize revenue under ASC 606 rather than under the lease accounting guidelines, since the predominant component of revenue is the non-lease component. Our fixed monthly equipment rentals to customers are accounted for as operating leases under ASU 2016-02, Leases (ASC 842). Fixed monthly rentals provide for a flat rental fee each month. A limited number of our contracts have variable consideration including tiered pricing and rebates which we monitor closely for potential constraints on revenue. For these contracts, we estimate our position quarterly using the most-likely-outcome method, including customer-provided forecasts and historical buying patterns, and we accrue for any asset or liability these arrangements may create. The effect of accruals for variable consideration on our consolidated financial statements is immaterial. We do not disclose the value of unsatisfied performance obligations for contracts for which we recognize revenue at the amount which we have the right to invoice. We believe that the complexity added to our disclosures by the inclusion of a large amount of insignificant detail in attempting to disclose information under ASC 606 about immaterial contracts would potentially obscure more useful and important information. |
Leases to Customers | The lease assets from our sales-type leases are recorded in our accounts receivable in the accompanying consolidated balance sheets, and the balance totaled $356 thousand as of December 31, 2022 and $470 thousand as of December 31, 2021. Our equipment treated as leases to customers is included in Property, Plant, and Equipment on our consolidated balance sheets. Due to the immaterial amount of revenue and assets from our lessor activity, all other lessor disclosures have been omitted. |
Leased Property and Equipment | As a lessee, we had eight leases in total for equipment and facilities used internally during 2022, which we account for as operating leases. At December 31, 2022, our right-of-use asset balance was $683 thousand and our lease liability at December 31, 2022 for these leases was $672 thousand. The monthly expense of $43 thousand for these operating leases, which are our only lessee arrangements, is immaterial and therefore all other lessee disclosures have been omitted. |
Research and Development Costs | Research and Development, or R&D, costs relating to the development of new products and improvements of existing products are expensed as incurred. |
Stock-Based Compensation | We have a stock-based compensation plan covering certain of our officers, directors, key employees, and non-physician consultants. As explained in detail in Note 8, we account for stock-based compensation utilizing the fair value recognition provisions of ASC 718, Compensation-Stock Compensation, |
Liability-classified awards | The Company classifies certain awards that can or will be settled in cash as liability awards. The fair value of a liability-classified award is determined on a quarterly basis beginning at the grant date until final vesting. Changes in the fair value of liability-classified awards are recorded to general and administrative expense over the vesting period of the award. |
New Accounting Pronouncements | From time to time new accounting pronouncements applicable to us are issued by the FASB, or other standards setting bodies, which we adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption. |
Fair Value Measurements | Accounting standards use a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists therefore requiring an entity to develop its own assumptions. As of December 31, 2022 and 2021, we held investments in commercial paper, bonds, money market funds, mutual funds, and equity securities that are required to be measured for disclosure purposes at fair value on a recurring basis. The fair values of these investments and their tier levels are shown in Note 2. The carrying values of our other financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and accrued income and other taxes approximated fair value due to their liquid and short-term nature. |
Concentration of Credit Risk | Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, and accounts receivable. Our cash deposits are held in accounts with financial institutions that we believe are creditworthy. Certain of these amounts at times may exceed federally-insured limits. We have investments in money market funds, bonds, equity securities, and commercial paper. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, changes in credit quality of the issuer, and otherwise. These securities have a higher degree of, and a greater exposure to, credit or default risk and may be less liquid in times of economic weakness or market disruptions as compared with cash deposits. For accounts receivable, we perform ongoing credit evaluations of our customers’ financial condition and generally do not require collateral. We maintain reserves for possible credit losses. We had allowances for doubtful accounts of approximately $71 thousand at December 31, 2022 and $69 thousand, at December 31, 2021. The carrying amount of the receivables approximates their fair value. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Summary of Significant Accounting Policies | |
Schedule of Cash and Cash equivalents | December 31, 2022 December 31, 2021 Cash and cash equivalents: Cash deposits $ 603 $ 2,388 Money market funds 2,380 29,876 Commercial paper 1,748 - Total cash and cash equivalents $ 4,731 $ 32,264 Short-term investments: Commercial paper (held-to-maturity) $ 12,227 $ 2,248 Bonds (held-to-maturity) 8,597 26,831 Equity Securities (available for sale) 330 - Allowance for credit losses (2 ) (20 ) Total short-term investments $ 21,152 $ 29,059 Long-term investments: Equity securities (available for sale) $ 5,139 $ 5,468 Bonds (held-to-maturity) 3,180 13,405 Mutual funds (available for sale) 350 559 Allowance for credit losses - (9 ) Total long-term investments $ 8,669 $ 19,423 Total cash, cash equivalents and short and long-term investments $ 34,552 $ 80,746 |
Schedule of Inventories | December 31, 2022 2021 Raw materials $ 33,329 $ 23,733 Work in process 13,618 9,571 Finished goods 18,846 17,474 Total inventories $ 65,793 $ 50,778 |
Schedule of Property, Plant and Equipment | December 31, Useful 2022 2021 Lives Land $ 5,511 $ 5,511 — Buildings 60,984 38,223 30-40 yrs. Machinery and equipment 204,147 189,483 3-15 yrs. Total property, plant and equipment $ 270,642 $ 233,217 |
Schedule of Current Accrued Liabilities | December 31, 2022 2021 Accrued payroll and related expenses $ 4,718 $ 4,988 Accrued vacation 408 387 Other accrued liabilities 824 555 Total accrued liabilities $ 5,950 $ 5,930 |
Schedule of geographic area | Year ended December 31, 2022 2021 2020 United States $ 109,740 $ 96,925 $ 85,682 European Union 30,311 28,657 27,786 All other regions 43,455 39,427 34,123 Total $ 183,506 $ 165,009 $ 147,591 |
Schedule of product line Information | Year ended December 31, 2022 2021 2020 Fluid Delivery $ 84,084 $ 77,753 $ 75,228 Cardiovascular 67,632 56,919 48,524 Ophthalmology 5,849 6,332 4,700 Other 25,941 24,005 19,139 Total $ 183,506 $ 165,009 $ 147,591 |
Investments (Tables)
Investments (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Investments | |
Schedule of investments, held-to-maturity securities | Held-to-Maturity Bonds Credit Quality Indicators Fed Govt. Bonds/Notes Municipal Bonds Corporate Bonds Total AA/A $ 180 $ - $ 3,044 $ 3,224 BBB - - 8,553 8,553 TOTAL $ 180 $ - $ 11,597 $ 11,777 |
Schedule of unrealized gains and losses | Gross Unrealized Level Cost Gains Losses Fair Value As of December 31, 2022: Money market funds 1 $ 2,380 $ - $ - $ 2,380 Commercial paper 2 $ 13,975 $ 1 $ (9 ) $ 13,967 Bonds 2 $ 11,777 $ - $ (353 ) $ 11,424 Mutual funds 1 $ 466 $ - $ (116 ) $ 350 Equity investments 2 $ 6,054 $ - $ (585 ) $ 5,469 As of December 31, 2021: Money market funds 1 $ 29,876 $ - $ - $ 29,876 Commercial paper 2 $ 2,248 $ - $ - $ 2,248 Bonds 2 $ 40,236 $ 97 $ (37 ) $ 40,296 Mutual funds 1 $ 558 $ 1 $ - $ 559 Equity investments 2 $ 5,675 $ - $ (207 ) $ 5,468 |
Patents and Licenses (Tables)
Patents and Licenses (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Patents and Licenses | |
Schedule of Patents and Licenses | December 31, 2022 December 31, 2021 Weighted Average Original Life (years) Gross Carrying Amount Accumulated Amortization Weighted Average Original Life (years) Gross Carrying Amount Accumulated Amortization 15.67 $ 13,840 $ 12,655 15.67 $ 13,840 $ 12,538 |
Schedule of Future Amortization Expense | 2023 $ 113 2024 $ 113 2025 $ 112 2026 $ 112 2027 $ 108 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Taxes | |
Schedule of Provision for Income Taxes | Year ended December 31, 2022 2021 2020 Current — Federal $ 8,030 $ 7,445 $ 3,166 — State 773 1,615 904 8,803 9,060 4,070 Deferred — Federal (3,021 ) (3,349 ) 2,111 — State (173 ) (337 ) 171 (3,194 ) (3,686 ) 2,282 Provision for Income Taxes $ 5,609 $ 5,374 $ 6,352 |
Schedule of Deferred Tax Assets And Liabilities | 2022 2021 Deferred tax assets Benefit plans $ 1,421 $ 1,853 Inventories 730 336 Capitalized R&D 2,275 -- Total deferred tax assets 4,426 2,189 Valuation allowance -- (36 ) Net deferred tax assets 4,426 2,153 Deferred tax liabilities Property, plant, and equipment 6,334 7,289 Patents and goodwill 1,745 1,773 Other 235 173 Total deferred tax liabilities 8,314 9,235 Net deferred tax liabilities $ 3,888 $ 7,082 |
Schedule of Statutory Federal Income Tax Rate | Year ended December 31, 2022 2021 2020 Income tax expense at the statutory federal income tax rate $ 8,530 $ 8,070 $ 8,078 Increase (decrease) resulting from: State income taxes 438 1,027 839 R&D tax credits (1,332 ) (1,703 ) (1,589 ) Foreign-derived intangible income deduction (2,133 ) (2,091 ) (1,051 ) Excess tax benefit from stock compensation (97 ) (185 ) (81 ) Uncertain tax positions -- -- (450 ) Other, net 203 256 606 Provision for Income Taxes $ 5,609 $ 5,374 $ 6,352 |
Schedule of gross unrecognized tax benefits | Gross unrecognized tax benefits at January 1, 2020 $ 450 Increase in tax positions for prior years 8 Increase in tax positions for current years -- Lapse in statutes of limitation (458 ) Gross unrecognized tax benefits at December 31, 2020 $ -- Increase in tax positions for prior years -- Increase in tax positions for current year -- Lapse in statutes of limitation -- Gross unrecognized tax benefits at December 31, 2021 $ -- Increase in tax positions for prior years -- Increase in tax positions for current year -- Lapse in statutes of limitation -- Gross unrecognized tax benefits at December 31, 2022 $ -- |
Income Per Share (Tables)
Income Per Share (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Per Share | |
Schedule of Computation for Basic and Diluted Income Per Share | Year ended December 31, 2022 2021 2020 (In thousands, except per share amounts) Net Income $ 35,008 $ 33,055 $ 32,115 Weighted average basic shares outstanding 1,787 1,814 1,836 Add: Effect of dilutive securities 3 4 5 Weighted average diluted shares outstanding 1,790 1,818 1,841 Net Income per share Basic $ 19.59 $ 18.22 $ 17.49 Diluted $ 19.56 $ 18.18 $ 17.44 |
Stockbased Compensation (Tables
Stockbased Compensation (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Stockbased Compensation | |
Schedule of stock option transactions | Options Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Outstanding at December 31, 2021 8,000 $ 501.03 0.3 years Granted -- -- Exercised 8,000 -- Outstanding at December 31, 2022 -- -- -- |
Schedule of restricted stock units | Nonvested Stock Units Restricted Stock Units Weighted Average Award Date Fair Value Per Unit Director’s Stock Units Weighted Average Award Date Fair Value Per Unit Nonvested at December 31, 2021 4,171 $ 666.14 -- Granted & Added 644 $ 618.99 7 $ 616.83 Forfeited (374 ) $ 649.30 -- Vested (1,711 ) $ 613.21 (7 ) $ 616.83 Nonvested at December 31, 2022 2,730 $ 690.50 -- |
Schedule of non- vested restricted stock | Nonvested Shares Shares Weighted Average Award Date Fair Value Per Share Restricted stock at December 31, 2021 1,180 $ 445.47 Granted -- -- Vested (1,180 ) $ 445.47 Restricted stock at December 31, 2022 -- -- |
Schedule of stock based compensation | Unrecognized Compensation Cost Weighted Average Remaining Years in Amortization Period Stock options $ -- -- Restricted stock -- -- Restricted stock units 1,079 3.4 Restricted stock units (to be settled in cash) 1,304 2.5 Total $ 2,383 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Cash and cash equivalents | ||
Cash deposits | $ 603,000 | $ 2,388,000 |
Money market funds | 2,380,000 | 29,876,000 |
Commercial paper | 1,748 | 0 |
Total cash and cash equivalents | 4,731,000 | 32,264,000 |
Short-term investments | ||
Commercial paper (held-to-maturity) | 12,227,000 | 2,248,000 |
Bonds (held-to-maturity) | 8,597,000 | 26,831,000 |
Equity securities (available for sale) | 330,000 | 0 |
Allowance for credit losses | (2,000) | (20,000) |
Total short-term investments | 21,152,000 | 29,059,000 |
Long-term investments | ||
Equity securities (available for sale) | 5,139,000 | 5,468,000 |
Bonds (held-to-maturity) | 3,180,000 | 13,405,000 |
Mutual funds (available for sale) | 350 | 559,000 |
Allowance for credit losses | 0 | (9,000) |
Total long-term investments | 8,669,000 | 19,423,000 |
Total cash, cash equivalents and short and long-term investments | $ 34,552,000 | $ 80,746,000 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies (Details 1) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Summary of Significant Accounting Policies | ||
Raw material | $ 33,329 | $ 23,733 |
Work in process | 13,618 | 9,571 |
Finished goods | 18,846 | 17,474 |
Total inventories | $ 65,793 | $ 50,778 |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies (Details 2) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Total Property, plan and Equipment | $ 270,642 | $ 233,217 |
Property, Plant And Equipment Net | 123,754 | 97,972 |
Land [Member] | ||
Property, Plant And Equipment Net | 5,511 | 5,511 |
Buildings [Member] | ||
Property, Plant And Equipment Net | 60,984 | 38,223 |
Machinery and Equipment [Member] | ||
Property, Plant And Equipment Net | $ 204,147 | $ 189,483 |
Minimum [Member] | Buildings [Member] | ||
Property and Equipment estimated useful lives | 30 years | |
Minimum [Member] | Machinery and Equipment [Member] | ||
Property and Equipment estimated useful lives | 3 years | |
Maximum [Member] | Buildings [Member] | ||
Property and Equipment estimated useful lives | 40 years | |
Maximum [Member] | Machinery and Equipment [Member] | ||
Property and Equipment estimated useful lives | 15 years |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies (Details 3) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Summary of Significant Accounting Policies | ||
Accrued payroll and related expenses | $ 4,718 | $ 4,988 |
Accrued vacation | 408 | 387 |
Other accrued liabilities | 824 | 555 |
Total accrued liabilties | $ 5,950 | $ 5,930 |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies (Details 4) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Total Revenues | $ 183,506 | $ 165,009 | $ 147,591 |
European Union [Member] | |||
Total Revenues | 30,311 | 28,657 | 27,786 |
All Other Regions [Member] | |||
Total Revenues | 43,455 | 39,427 | 34,123 |
United State [Member] | |||
Total Revenues | $ 109,740 | $ 96,925 | $ 85,682 |
Summary of Significant Accoun_9
Summary of Significant Accounting Policies (Details 5) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Total Revenues | $ 183,506 | $ 165,009 | $ 147,591 |
Other | 25,941 | 24,005 | 19,139 |
Fluid Delivery [Member] | |||
Total Revenues | 84,084 | 77,753 | 75,228 |
Cardiovascular [Member] | |||
Total Revenues | 67,632 | 56,919 | 48,524 |
Ophthalmology [Member] | |||
Total Revenues | $ 5,849 | $ 6,332 | $ 4,700 |
Summary of Significant Accou_10
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Summary of Significant Accounting Policies | |||
Income taxes due | $ 1,000,000 | $ 345,000 | |
Goodwill | 9,730,000 | 9,730,000 | |
Allowances for doubtful accounts | 71,000 | 69,000 | |
Monthly expense | 43,000 | ||
Right- of- use- asset | 683,000 | ||
Lease liability | 672,000 | ||
Accounts receivable | $ 356,000 | 470,000 | |
Payment due | 30 | ||
Useful lives | 20 years | ||
Depereciation expense | $ 13,695 | 12,767 | $ 11,533 |
Accounts payable | 887,000 | $ 1,989 | |
Accounts payable and accrued liablities | $ 5,700,000 |
Investments (Details)
Investments (Details) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Money Market Funds [Member] | ||
Debt Securities, Held-to-maturity | $ 2,380,000 | $ 29,876,000 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Gross Unrealized Fair Value | 2,380,000 | 29,876,000 |
Commercial Paper [Member] | ||
Debt Securities, Held-to-maturity | 13,975,000 | 2,248,000 |
Gross Unrealized Gains | 1,000 | 0 |
Gross Unrealized Losses | (9,000) | 0 |
Gross Unrealized Fair Value | 13,967,000 | 2,248,000 |
Bonds [Member] | ||
Debt Securities, Held-to-maturity | 11,777,000 | 40,236,000 |
Gross Unrealized Gains | 0 | 97,000 |
Gross Unrealized Losses | (353,000) | (37,000) |
Gross Unrealized Fair Value | 11,424,000 | 40,296,000 |
Mutual funds (available for sale) [Member] | ||
Debt Securities, Held-to-maturity | 466,000 | 558,000 |
Gross Unrealized Gains | 0 | 1,000 |
Gross Unrealized Losses | (116,000) | 0 |
Gross Unrealized Fair Value | 350,000 | 559,000 |
Equity investments [Member] | ||
Debt Securities, Held-to-maturity | 6,054,000 | 5,675,000 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (585,000) | (207,000) |
Gross Unrealized Fair Value | $ 5,469,000 | $ 5,468,000 |
Investments (Details 1)
Investments (Details 1) | Dec. 31, 2022 USD ($) |
AAA /AA/A [Member] | |
Debt Securities, Held-to-maturity | $ 3,224,000 |
BBB/BB [Member] | |
Debt Securities, Held-to-maturity | 8,553,000 |
Municipal Bonds [Member] | |
Debt Securities, Held-to-maturity | 0 |
Municipal Bonds [Member] | AAA /AA/A [Member] | |
Debt Securities, Held-to-maturity | 0 |
Municipal Bonds [Member] | BBB/BB [Member] | |
Debt Securities, Held-to-maturity | 0 |
Corporate Bonds [Member] | |
Debt Securities, Held-to-maturity | 11,597,000 |
Corporate Bonds [Member] | AAA /AA/A [Member] | |
Debt Securities, Held-to-maturity | 3,044,000 |
Corporate Bonds [Member] | BBB/BB [Member] | |
Debt Securities, Held-to-maturity | 8,553,000 |
Fed Govt. Bonds/Notes [Member] | |
Debt Securities, Held-to-maturity | 180,000 |
Fed Govt. Bonds/Notes [Member] | BBB/BB [Member] | |
Debt Securities, Held-to-maturity | 0 |
Common Stocks | |
Total held to Maturity Bonds | 11,777 |
Debt Securities, Held-to-maturity | $ 180,000 |
Investments (Details Narrative)
Investments (Details Narrative) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Investments | ||
Securities Maturity, Description | currently own ranged from one to 36 months and the length of time until maturity of the commercial paper ranged from one to four months | |
Allowance for credit losses related to long term investments | $ 2 | $ 29 |
Patents and Licenses (Details)
Patents and Licenses (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Patents and Licenses | ||
Accumulated Amortization | $ 12,655 | $ 12,538 |
Weighted Average Original Life (years) | 15 years 8 months 1 day | 15 years 8 months 1 day |
Gross Carrying Amount | $ 13,840 | $ 13,840 |
Patents and Licenses (Details 1
Patents and Licenses (Details 1) $ in Thousands | Dec. 31, 2021 USD ($) |
Patents and Licenses | |
2023 | $ 113 |
2024 | 113 |
2025 | 112 |
2026 | 112 |
2027 | $ 108 |
Patents and Licenses (Details N
Patents and Licenses (Details Narrative) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Patents and Licenses | ||
Aggregate amortization expense | $ 117 | $ 119 |
Line of Credit (Details Narrati
Line of Credit (Details Narrative) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Line of Credit | ||
Credit facility | $ 75,000,000 | $ 75,000,000 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Taxes | |||
Federal income tax, current | $ 8,030 | $ 7,445 | $ 3,166 |
State income tax, current | 773 | 1,615 | 904 |
Income tax, current | 8,803 | 9,060 | 4,070 |
Federal income tax, deferred | (3,021) | (3,349) | 2,111 |
State income tax, deferred | (173) | (337) | 171 |
Income tax, deferred | (3,194) | (3,686) | 2,282 |
Provision for Income Taxes | $ 5,609 | $ 5,374 | $ 6,352 |
Income Taxes (Details 1)
Income Taxes (Details 1) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Deferred tax liabilities (assets): | ||
Benefit plans | $ 1,421,000 | $ 1,853,000 |
Inventories | 730,000 | 336,000 |
Capital loss carryover | 2,275,000 | 0 |
Total deferred tax assets | 4,426,000 | 2,189,000 |
Plus: Valuation allowance | 0 | (36,000) |
Net deferred tax assets | 4,426,000 | 2,153,000 |
Property, plant and equipment | 6,334,000 | 7,289,000 |
Patents and goodwill | 1,745,000 | 1,773,000 |
Others | 235,000 | 173,000 |
Total deferred tax liabilities | 8,314,000 | 9,235,000 |
Net Deferred Tax Liabilities | $ 3,888,000 | $ 7,082,000 |
Income Taxes (Details 2)
Income Taxes (Details 2) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Taxes | |||
Income tax expense at the statutory federal income tax rate | $ 8,530,000 | $ 8,070,000 | $ 8,078,000 |
Increase (decrease) resulting from: | |||
State income taxes | 438,000 | 1,027,000 | 839,000 |
R&D tax credits | (1,332,000) | (1,703,000) | (1,589,000) |
Foreign-derived intangible income deduction | (2,133,000) | (2,091,000) | (1,051,000) |
Excess tax benefit from stock compensation | (97,000) | (185,000) | (81,000) |
Uncertain tax positions | 0 | 0 | (450,000) |
Other, net | 203,000 | 256,000 | 606,000 |
Provision for Income Taxes | $ 5,609,000 | $ 5,374,000 | $ 6,352,000 |
Income Taxes (Details 3)
Income Taxes (Details 3) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Taxes | |||
Gross unrecognized tax benefits | $ 0 | $ 0 | $ 450,000 |
Increase in tax positions for prior years | 0 | 0 | 8,000 |
Increase in tax positions for current year | 0 | 0 | 0 |
Lapse in statutes of limitation | $ 0 | $ 0 | $ (458,000) |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Taxes | |||
Unrecognized tax benefits, net interest benefit | $ 0 | $ 0 | $ 35,000 |
Stockholders Equity (Details Na
Stockholders Equity (Details Narrative) - USD ($) | 12 Months Ended | ||||||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | May 21, 2015 | |
Stockholders' Equity: | |||||||
Non cash dividend amount | $ 30,000 | $ 24,000 | $ 24,000 | ||||
Cash dividend payments per share | $ 2.15 | $ 1.95 | $ 1.75 | ||||
Total repurchased shares of common stock | 42,568 | 27,828 | |||||
Stock repurchase program, shares remained eligible for repurchase | 131,622 | 174,190 | |||||
Stock repurchase program, shares authorized to be repurchased | 250,000 |
Income Per Share (Details)
Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Per Share | |||
Net income | $ 35,008 | $ 33,055 | $ 32,115 |
Weighted average basic shares outstanding | 1,787 | 1,814 | 1,836 |
Add: Effect of dilutive securities | 3 | 4 | 5 |
Weighted average diluted shares outstanding | 1,790 | 1,818 | 1,841 |
Earnings per share: | |||
Basic | $ 19.59 | $ 18.22 | $ 17.49 |
Diluted | $ 19.56 | $ 18.18 | $ 17.44 |
Income Per Share (Details Narra
Income Per Share (Details Narrative) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Per Share | |||
Shares excluded from computation of weighted average diluted shares outstanding | no shares | two | six |
Stockbased Compensation (Detail
Stockbased Compensation (Details) | 12 Months Ended |
Dec. 31, 2022 $ / shares shares | |
Shares | |
Outstanding at December 31, 2021 | shares | 8,000 |
Granted | shares | 0 |
Exercised | shares | 8,000,000 |
Outstanding at December 31, 2022 | shares | 0 |
Weighted Average Exercise Price | |
Outstanding at December 31, 2021 | $ / shares | $ 501.03 |
Granted | $ / shares | 0 |
Exercised | $ / shares | 0 |
Outstanding at December 31, 2022 | $ / shares | $ 0 |
Weighted Average Remaining Contractual Term | |
Weighted Average Remaining Contractual Term Outstanding | 3 months 18 days |
Stockbased Compensation (Deta_2
Stockbased Compensation (Details 1) | 12 Months Ended |
Dec. 31, 2022 $ / shares shares | |
Nonvested Shares | |
Nonvested restricted stock outstanding, beginning balance | shares | 1,180 |
Granted in 2021 | shares | 0 |
Vested in 2021 | shares | (1,180) |
Nonvested restricted stock outstanding, Ending balance | shares | 0 |
Weighted Average Award Date Fair Value Per Share | |
Weighted Average Award Date Fair Value Per Share, beginning balance | $ / shares | $ 445.47 |
Weighted Average Award Date Fair Value Per Share, Granted in 2021 | $ / shares | 0 |
Weighted Average Award Date Fair Value Per Share, Vested in 2021 | $ / shares | 445.47 |
Weighted Average Award Date Fair Value Per Share, Ending balance | $ / shares | $ 0 |
Stockbased Compensation (Deta_3
Stockbased Compensation (Details 2) | 12 Months Ended |
Dec. 31, 2022 $ / shares shares | |
Directors Stock Units [Member] | |
Nonvested Stock Units Added | 7 |
Nonvested Stock Units Forfeited | 0 |
Nonvested Stock Units Vested | (7) |
Restricted Stock Units [Member] | |
Novested Stock Units Beginning balance, Shares | 4,171 |
Nonvested Stock Units Added | 644 |
Nonvested Stock Units Forfeited | (374) |
Nonvested Stock Units Vested | (1,711) |
Novested Stock Units Ending balance, Shares | 2,730 |
Weighted Average Award Date Fair Value Per Unit, Beginning balance | $ / shares | $ 666.14 |
Weighted Average Award Date Fair Value Per Unit, Added | $ / shares | 618.99 |
Weighted Average Award Date Fair Value Per Unit, Vested | $ / shares | 613.21 |
Weighted Average Award Date Fair Value Per Unit, Forfeited | $ / shares | 649.30 |
Weighted Average Award Date Fair Value Per Unit, Ending balance | $ / shares | 690.50 |
Weighted Average Award Date Fair Value Per Unit [Member] | |
Weighted Average Award Date Fair Value Per Unit, Added | $ / shares | 616.83 |
Weighted Average Award Date Fair Value Per Unit, Vested | $ / shares | $ 616.83 |
Stockbased Compensation (Deta_4
Stockbased Compensation (Details 3) | 12 Months Ended |
Dec. 31, 2022 USD ($) | |
Total Unrecognized Compensation Cost | $ 2,383,000 |
Stock Option [Member] | |
Unrecognized Compensation Cost | $ 0 |
Weighted Average Remaining Years in Amortization Period | 0 years |
Restricted Stock Units [Member] | |
Weighted Average Remaining Years in Amortization Period | 3 years 4 months 24 days |
Unrecognized Compensation Cost | $ 1,079,000 |
Restricted Stock [Member] | |
Weighted Average Remaining Years in Amortization Period | 0 years |
Unrecognized Compensation Cost | $ 0 |
Restricted stock units (to be settled in cash) [Member] | |
Weighted Average Remaining Years in Amortization Period | 2 years 6 months |
Unrecognized Compensation Cost | $ 1,304,000 |
Stockbased Compensation (Deta_5
Stockbased Compensation (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Discount percentage for post vesting restrictions | 11.20% | ||
Cash paid for post vesting restrictions | $ 524,000 | $ 485,000 | |
Fair value restricted stock awards vested | 796,000 | 754,000 | $ 762,000 |
Accrued dividend equivalents | 1,304,000 | ||
Stock-based compensation expense, total tax benefit recognized | 461,000 | 1,203,000 | 444,000 |
Total fair value of stock units that vested | 227,000 | ||
Stock-based compensation expense | 1,730,000 | 2,312,000 | 1,731,000 |
Non Employee Directors [Member] | |||
Value of stock units held for the accounts | 1,800,000 | ||
Non Employee Directors [Member] | 2006 Plan [Member] | |||
Total value of stock awards | 492,000 | 432,000 | |
Directors [Member] | |||
Total fair value of stock units that vested | $ 4,000 | $ 4,000 | $ 11,000 |
2006 Equity Incentive Plan | |||
Weighted average grant date fair value | $ 646.90 | ||
Number of common shares reserved for future issuance | 200,000 | ||
Granted shares of restricted stock | 3,865 | ||
2006 Equity Incentive Plan | Restricted Stock [Member] | |||
Terms of award | the restrictions usually lapse over a five-year period | ||
2021 Equity Incentive Plan | |||
Number of common shares reserved for future issuance | 100,000 |
Industry Segment and Geograph_2
Industry Segment and Geographic Information (Details Narrative) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue from sales | 40% | 41% | 42% |
Employee Retirement and Benef_2
Employee Retirement and Benefit Plans (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Employee Retirement and Benefit Plans | |||
Employees compensation contribution | $ 1,061 | $ 980,000 | $ 917,000 |
Deferred compensastion obligation | $ 2,355,000 | $ 2,031,000 |
Commitment and contingencies (D
Commitment and contingencies (Details Narrative) $ in Millions | Dec. 31, 2022 USD ($) |
Lease obligations | $ 1 |
Future payments | 5.4 |
Three And Four Executive Officers [Member] | |
Aggeregate amount of employees | $ 67.2 |